You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company, founded earlier this year, is developing a technology for the detection of low-frequency genetic mutations for diagnostic applications.
The company is developing a test to predict the risk of a melanoma patient's cancer metastasizing in lymph nodes without the need for biopsy.
The firm did not disclose the size of the funding, which is helping it build on its Centrellis Health Intelligence Platform and move to whole-exome sequencing.
The Tokyo-based firm said it will use the funding to support prototyping and commercialization of its mass spectrometry and optical spectroscopy instruments.
The firm said it will use the funding to invest in research and development that will improve upon its deep shotgun metagenomic sequencing technology.
The German firm has developed a PCR technology that rapidly regulates temperature with so-called microcyclers diffused in the master mix solution.
Formerly known as Diassess, the Emeryville, California-based startup will use the funding to finance regulatory clearances and early commercialization.
The firm said that the new funds will enable it to build on the continued commercial expansion of its first product, PredictSure IBD, in the coming months.
X Gen US, a California startup led by a veteran sequencing tools developer, says its kits can create single-cell RNA-seq libraries in less than two hours.
The company recently launched Prompt Prostate Genetic Score, a lab-developed test to track a man's genetic predisposition to prostate cancer.
Following discrimination allegations, NICHD's Constantine Stratakis withdraws from a new position at the Research Institute of the McGill University Health Center, Science reports.
US President Donald Trump has threatened to cut World Health Organization funding over its pandemic response, which would affect its ability to do its work and which he might not be able to do.
The US Securities and Exchange Commission has halted the sales of a handful of stocks over claims made about the coronavirus.
In Nature this week: comparative analyses of single-cell RNA sequencing protocols uncover differences between approaches, and more.